2/ Also, it's all very mechanistic, with ANGPTL4 vs. 3/8 being oppositely regualted by feeding and fasting in a tissue specific manner such that fasting decreases fat storage in adopicytes and feeding promotes it.
And, perhaps, unsuprislingly, the lipid metabolism is...
3/ w.r.t ANGPTLs (and specifically 4, which controls local LPL activity) is linked with glucose homeostasis...
4/ Also, exercise locally induces ANGPTL4 in adipocytes so as to direct fat fuel to working muscles.
1/6) Today’s video on statins (linked below) dives into several key studies you need to understand, along with some provocative demonstrations that will definitely stick in your brain.
But in this short thread, let’s quickly review a few major takeaways...
2/6) Take Away 1: Across the board—whether you're looking at the 4S trial or more recent datasets involving cardiac imaging—a consistent pattern emerges:
People with good metabolic health and/or a zero-calcium score may see minimal benefit from statin therapy or LDL reduction.
Now, of course, there are nuances.
But broadly speaking, if your coronary artery calcium (CAC) score is zero, there's little to no reduction in cardiovascular events from lowering LDL.
3/6) And even if there is a tiny marginal benefit on subclinical progression at a population level (being generous)... does it outweigh the risks?
Statins are often treated as benign. They are not.
Side effects include—and go beyond—muscle pain:
↑ Insulin resistance
↓ GLP-1 levels (Shown, Atorvastatin vs Control)
↑ Risk of diabetes
Potential long-term muscle loss
Variable brain effects
This isn’t to say statins don’t have a place. It’s to say: the risk-benefit analysis must include actual risks.
Have High Lp(a)? You Need to See Today's Video covering a new 2025 study on Lp(a) and waist-to-hip ratio
1/5) Here's a quick breakdown...
The goal of this new study was to determine whether a measure of adiposity—waist-to-hip ratio—modifies the relationship between Lp(a) and cardiovascular disease risk.
2/5) To explore this, researchers analyzed data from 4,652 participants in the Multi-Ethnic Study of Atherosclerosis (MESA), following them over a median of 17.4 years.
The study stratified individuals based on Lp(a) levels defined as >50 mg/dL and investigated how this risk interacted with waist-to-hip ratio as a marker of central adiposity and visceral fat
*Lp(a) (nmol/L) = Lp(a) (mg/dL) x 2.15
3/5) And—remarkably—in individuals with a ↓ waist-to-hip ratio, Lp(a) levels were not significantly associated with increased cardiovascular risk…
New Study: Person Study Finds Statin Use Associated Decline in Muscle Mass
1/6) A colleague of mine—a medical doctor—texted me recently: “I’m stopping my statin.”
The new paper referenced concludes: “Continuous statin use is associated with a decline in muscle function and mass over time (25% decline in grip strength and 73% decline in appendicular lean mass compared to never- users).”
Let’s discuss. (links in 5/6 and 6/6)
2/6) We’ll break this up by discussing the cross-sectional (single time point) and longitudinal (over time) results.
Cross-sectional analysis: In the fully adjusted model, adjusting for age, sex, education, smoking, BMI, activity score, diet quality score, high blood pressure, diabetes, and so on, statin use was associated with lower grip strength and lower appendicular lean mass.
3/6) Longitudinal Analysis: Statin Use Associated with Steeper Muscle Decline
Echoing the prior analysis, continuous statin use was significantly associated with accelerated declining grip strength and lean mass.
*Nuance note: For those with keen eyes, we discuss the y-intercept in the full letter
TL;DR: Statins use is linked to fasting muscular decline.
2/8) As a quick recap, I recently did a self-experiment that can be summarized in just two words: Sardine Diet. After a couple weeks on this extremely high omega-3 diet, I became conspicuously cold-resistant.
This was weird.
And I wanted to understand what might be happening. So, I dug into the literature.
3/8) Here's what could be happening...
Metabolically active brown fat can convert omega-3 fatty acids into a hormone called 12-HEPE.
12-HEPE stimulates thermogenesis in brown fat and ramps up glucose uptake into muscle as well.
This ultimately promotes heat production, cold adaptation, and energy expenditure.
(1/8) Alzheimer’s disease is personal for me. In my early 20s, I discovered I carry the ApoE4/4 genotype—placing me at the highest genetic risk. I was terrified. But over time, that fear shifted to a realization:
👉A genetic predisposition is a vulnerability, not a destiny.
👉 Our choices shape our health trajectory more than our genes ever could.
Today, I want to share a piece of that puzzle: The Omega-3 Paradox.
👉The Signal: Data clearly shows eating fatty fish lowers Alzheimer’s rates and boosts cognitive longevity.
👉The Failure: Yet, large clinical trials using Omega-3 supplements often fail to protect the brain.
👉The Question: Why?
One answer lies in a specific delivery mechanism most people—and many researchers—overlook.
Here is the science of getting Omega-3s into the brain. 🧵👇
(2/8) So, why do supplements often miss the mark? The answer is likely the form in which the Omega-3s are packaged.
When you eat seafood, you ingest Omega-3s in diverse forms, including phospholipids. However, most supplements on the shelf provide them in other forms, like triglycerides.
The Form Matters…
(3/8) The Form of Omega-3 Matters.
Think of it like this: Consuming DHA as a free fatty acid triglyceride is like mailing a letter with no address. It enters your system, but it doesn't know where to go. It rarely reaches the brain.
But if you have phospholipid-bound DHA? That’s like sending a letter via express courier, straight to the correct neuron. More specifically, the “express courier” form is called Lyso-DHA.
This specific form has special access to the brain through a transporter called MFSD2A.
Without the phospholipid "address," the DHA gets lost in transit.
How Metabolic Disease Feeds Emotional Eating 🧠🍩
(link at the end)
1/8) A brand new study (Dec 10, 2025) reveals how poor metabolic health can drive emotional eating.
Why this is important: There’s a known link between metabolic disease (obesity, diabetes, etc.) and mental health conditions (eating disorders, anxiety, depression).
But the causal relationships remain murky.
In uncovering the “how” we lay the groundwork for innovative solutions.
cc @Metabolic_Mind @janellison @TuitNutrition @ChrisPalmerMD @MitoPsychoBio @WilliamFurness @drjenunwin
2/8) The researchers behind the experiments took interest in ImP, which is known to be elevated in patients with metabolic conditions like diabetes (below)—and is linked to cardiometabolic disease.
*ImP levels are elevated in humans with type 2 diabetes (red) vs healthy controls (blue).
3/8) Given the link between metabolic diseases and mental health, the researchers set out to test a new hypothesis:
If you increase ImP, does that change the brain and behavior?
To do this, they fitted mice with a tiny pump that continuously delivered ImP at levels designed to mimic what’s seen in people with diabetes.
Afterward, they looked for neural changes and found a large shift in gene-expression programs within neurons tied to the stress response in the hypothalamus.